12:00 AM
Apr 16, 2007
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Organoselenium: Phase II start

Next quarter, ALT will start a Phase II trial in diabetic patients expressing the Haptoglobin 2-2 genotype. The company got an...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >